Market Overview

Sarepta Share Price Doubles Since Benzinga Broke News of Dr. Farkas' FDA Departure

Share:
Sarepta Share Price Doubles Since Benzinga Broke News of Dr. Farkas' FDA Departure
Related SRPT
Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl
Benzinga's Option Alert Recap From February 13
Biotech Forum Daily Digest: Trevena Oversold? Bristol-Myers Squibb On The Block? Can Portola Continue To Rally? (Seeking Alpha)

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) shot up this week as the FDA announced an accelerated approval of the company’s treatment for Duchenne Muscular Dystrophy, Eteplirsen.

Sarepta’s star continued to shine brightly as the company announced pricing for its drug Monday night.

Traders and investors could have seen this coming as early as the evening of September 13 by following news on the Benzinga Pro platform. Benzinga analysts were first to confirm Twitter reports that a regulator opposed to Sarepta’s treatment had left the agency.

Since that initial report, the company’s share price has more than doubled. It sat at $56.47 at press time, from $25.60 at the time of that initial report.

Benzinga analysts have seen double-digit share price movements off multiple breaking stories in recent weeks, including Weight Watchers International Inc (NYSE: WTW) and Zillow Group Inc (NASDAQ: Z).

Those interested in trying the Benzinga Pro platform can request a free trial here.

Posted-In: News Exclusives Movers Trading Ideas Best of Benzinga

 

Related Articles (WTW + SRPT)

View Comments and Join the Discussion!